comparemela.com

நேரம் ஃபின்னி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GetSwift class action reaches settlement agreement

GetSwift class action reaches settlement agreement GetSwift class action reaches settlement agreement Respondents to make a “modest” upfront payment into the pool, with further sums to come from the company over a three-year period. Credit: Supplied A class action against beleaguered Australian founded technology start-up GetSwift has reached a conditional settlement agreement for an unknown figure. The settlement agreement, which was entered into on 13 July and sees no admission of liability, will see respondents, GetSwift and director Joel Macdonald, make a “modest” upfront payment into the settlement pool.  Additionally, further sums will be contributed as a capped percentage of any capital raising, or a capped percentage of company revenue as a backstop if no or limited runs are raised, over a three-year period. 

There s always a way forward : Crunchtime for Mesoblast as legal threats loom

There s always a way forward : Crunchtime for Mesoblast as legal threats loom
smh.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from smh.com.au Daily Mail and Mail on Sunday newspapers.

Why does the Mesoblast (ASX:MSB) share price keep falling?

Why does the Mesoblast (ASX:MSB) share price keep falling? Brooke Cooper | May 11, 2021 5:28pm | More on: Shares in Mesoblast Limited(ASX: MSB) were once the talk of the ASX, but they’ve been plummeting recently. The Mesoblast share price has fallen 11.5% since the company’s last announcement on 30 April. In the April update, Mesoblast released its quarterly results and the results from those aged under 65 involved in its COVID-19 acute respiratory distress syndrome trial. But it’s what might not have been released that could have investors worried.  Class action lawsuits against Mesoblast Last week, the Australian Financial Review (AFR) reported that its attempts to get information from Mesoblast about participants of the trial aged over 65 had been unsuccessful.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.